Director Corporate Development

Company: Savant Recruitment Experts
Apply for the Director Corporate Development
Location: London
Job Description:

Corporate Development Manager

Location: London (Central)

Salary: £90,000 – £100,000 base + equity

Travel: 1 day per week (UK & Ireland)

Hybrid – 2 days in the office, 3 days WFH

We are working with a high-growth, PE-backed healthcare platform at a pivotal stage of its journey, executing an ambitious and well-funded buy-and-build strategy across the UK & Ireland.

With a strong pipeline of acquisition targets already identified, the business is now looking to appoint a Corporate Development Director to play a leading role in driving and executing its M&A agenda.

This individual will be instrumental in helping scale the platform through the acquisition of high-quality assets, working closely with the C-suite and investor group to deliver on its growth strategy.

This is a high-impact, front-office role, offering end-to-end exposure across the deal life-cycle, from origination and evaluation through to execution and integration.

You will be at the centre of strategic decision-making, helping shape the direction of the business as it continues to expand.

The role offers a rare opportunity to join a business early in its buy-and-build journey, where you will have genuine influence over deal activity, portfolio growth, and long-term value creation, with equity upside aligned to successful execution.

We are looking for someone with hands-on experience transacting in the lower mid-market (£2m- £5m deal size). Experience acquiring nurseries, special needs care homes, or nursing homes within a multi-site environment would be preferred.

Key Responsibilities

Deal Origination & Execution

  • Identify and engage with independent Healthcare practices across the UK & Ireland
  • Build relationships with brokers, advisors, and practice owners
  • Support pipeline development aligned to the group’s acquisition strategy

Financial Analysis & Due Diligence

  • Lead financial modelling and valuation analysis
  • Assess commercial viability of acquisition targets
  • Run and coordinate the full due diligence process (financial, operational, commercial)
  • Work closely with external advisors where required

Transaction Management

  • Draft and negotiate Letters of Intent (LOIs)
  • Prepare investment papers and presentations for the Investment Committee
  • Support deal structuring and completion

Stakeholder Management

  • Partner with CFO, CEO, and investors
  • Liaise with legal, financial, and operational advisors
  • Work closely with integration teams post-acquisition

Candidate Profile

Essential:

  • ACA or equivalent qualified accounting qualification (Top 10 / Big 4 preferred)
  • Strong academics
  • Background in:
  • M&A / Transaction Services / Corporate Finance
  • Ideally exposure to lower mid-market deals
  • Experience in healthcare advisory or multi-site environments highly desirable
  • Proven ability to:
  • Lead due diligence processes
  • Build financial models
  • Present investment cases

Highly Desirable:

  • Experience in buy-and-build environments
  • Exposure to private equity-backed businesses
  • Track record of executing deals end-to-end

What Success Looks Like

  • Successfully identifying and executing high-quality acquisitions
  • Delivering robust financial and commercial analysis
  • Building a strong deal pipeline across the UK & Ireland
  • Playing a key role in scaling a high-growth healthcare platform

Why Join?

  • Be part of a high-growth, entrepreneurial healthcare platform
  • Work directly with senior leadership and investors
  • Gain exposure to end-to-end deal execution
  • Participate in the equity upside of a scaling platform
  • Operate in a highly acquisitive, PE-style environment

This is a rare opportunity for a qualified accountant, trained M&A professional to step into a front-line corporate development role within a fast-scaling buy-and-build healthcare platform – with real ownership, deal exposure, and equity upside.

Posted: April 17th, 2026